Skip to main content
. Author manuscript; available in PMC: 2025 Feb 1.
Published in final edited form as: Am J Gastroenterol. 2023 Oct 27;119(2):262–269. doi: 10.14309/ajg.0000000000002532

Table 3.

Treatment and response data compared between White and non-White EoE patients

White
(n = 426)
Non-White
(n = 49)
p

Type of steroid used (n, %) 0.06
   Fluticasone 140 (33) 8 (16)
   Budesonide 285 (67) 41 (84)
Mean steroid dose (mcg ± SD) 1755 ± 711 1415 ± 635 0.002
Symptom response (n, %)* 130 (78) 9 (64) 0.27
Post-treatment peak eosinophil count (mean eos/hpf ± SD) 22.5 ± 34.3 39.0 ± 49.8 0.003
   p value vs baseline < 0.001 0.02
Histologic response (n, %)
   <15 eos/hpf 253 (59) 20 (41) 0.01
   ≤6 eos/hpf 223 (52) 18 (27) 0.04
   <1 eos/hpf 131 (31) 12 (24) 0.37
Post-treatment endoscopic findings (n, %)
   Normal 84 (20) 15 (31) 0.08
   Exudates 96 (23) 16 (33) 0.11
   Rings 206 (49) 7 (15) < 0.001
   Edema 114 (27) 17 (35) 0.24
   Furrows 192 (46) 20 (42) 0.58
   Stricture 145 (35) 8 (17) 0.01
   Narrowing 80 (19) 1 (2) 0.003
   Crepe-paper mucosa 3 (1) 1 (2) 0.33
   Dilation 139 (33) 8 (19) 0.04
   Candida 32 (8) 2 (4) 0.38
Endoscopic response (n, %) 311 (73) 26 (54) 0.006
Post-treatment endoscopic severity (mean scores ± SD)
   ERFES** 2.3 ± 1.9 2.2 ± 2.0 0.83
   p value vs baseline < 0.001 0.008
   ESS 1.8 ± 1.5 1.4 ± 1.5 0.09
   p value vs baseline < 0.001 0.13
*

available for 168 and 14;

**

available for 238 and 16